pegfp-c1-cadm1 (Shanghai GenePharma)
90
Structured Review
Shanghai GenePharma
pegfp-c1-cadm1
Pegfp C1 Cadm1, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pegfpc1+expression+vector/pmc09744787-98-1-8?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
Pegfp C1 Cadm1, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pegfpc1+expression+vector/pmc09744787-98-1-8?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
pegfp-c1-cadm1 - by Bioz Stars,
2026-08
90/100 stars
Images
1) Product Images from "Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data"
Article Title: Analysis of the key ligand receptor CADM1_CADM1 in the regulation of thyroid cancer based on scRNA-seq and bulk RNA-seq data
Journal: Frontiers in Endocrinology
doi: 10.3389/fendo.2022.969914
Figure Legend Snippet: Screening of crucial L/R pairs. (A) Venn diagram of 38 L/R pairs communicating between malignant cells/non-malignant cells and 44 L/R pairs communicating between non-malignant cells/malignant cells. (B) Forest plot of univariate Cox regression analysis of 16 L/R pairs. (C) KM curves of CADM1-CADM1.
Techniques Used:
Figure Legend Snippet: Differential analysis of 16 L/R pairs.
Techniques Used:
Figure Legend Snippet: Differences in the expression of CADM1-CADM1 in clinical phenotypes (** P < 0.01, *P < 0.05). The differences in CADM1-CADM1 by gender (A) , T stage (B) , M stage (C) , N stage (D) , stage (E) and age (F) . ns, no significance.
Techniques Used: Expressing
Figure Legend Snippet: Analysis of differential genes associated with CADM1-CADM1. (A) Volcano map showing differential genes between tumor tissues and para-tumors. (B) Bidirectional Clustering Heatmap showing the relationship between CADM1-CADM1 and differential genes associated with CADM1-CADM1. Each column in the heatmap represents a sample, and each row represents the expression level of a gene. The color scale beside the heatmap represents the raw Z-score: blue (low expression), red (high expression). (C) Scatter plot of 9 enriched GO terms of molecular function (MF). (D) Scatter plot of top 10 enriched GO terms of biological process (BP). (E) Scatter plot of top 10 enriched GO terms of cellular component (CC). (F) KEGG enrichment analysis of differential genes associated with CADM1-CADM1.
Techniques Used: Expressing
Figure Legend Snippet: Information of pathways involved in CADM1-CADM1.
Techniques Used:
Figure Legend Snippet: Box plots showing ssGSEA scores of related signaling pathways in high and low expression groups of CADM1-CADM1 (****P < 0.0001, *P < 0.05). (A) PI3K-Akt signaling pathway. (B) MAPK signaling pathway. (C) Wnt signaling pathway. (D) TGF-β signaling pathway. (E) JAK-STAT signaling pathway. (F) cAMP signaling pathway.
Techniques Used: Expressing
Figure Legend Snippet: The relationship between CADM1-CADM1 and DNA, RNA methylation. (A) Comparison of CADM1 methylation in high CADM1-CADM1 group and low CADM1-CADM1 group. (B) Correlation analysis of CADM1-CADM1 and CADM1 methylation. (C–E) Comparison of the scores of erasers, readers, writers in m1a, m6a, m5c modification between high CADM1-CADM1 group and low CADM1-CADM1 group separately (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05).
Techniques Used: Methylation, Modification
Figure Legend Snippet: The relationship between CADM1-CADM1, gender, age, stage, T stage, M stage, N stage and genes associated with apoptosis, ferroptosis, pyroptosis and cellular senescence.
Techniques Used:
Figure Legend Snippet: Comparison of targeted drug sensitivity in high CADM1-CADM1 group and low CADM1-CADM1 group. (****P < 0.0001, ***P < 0.001, *P < 0.05). (A) Comparison of the sensitivity of Erlotinib. (B) Comparison of the sensitivity of MG-132. (C) Comparison of the sensitivity of AZ628. (D) Comparison of the sensitivity of Sorafenib. (E) Comparison of the sensitivity of Saracatinib. (F) Comparison of the sensitivity of Dasatinib. (G) Comparison of the sensitivity of Parthenolide. (H) Comparison of the sensitivity of Bortezomib. (I) Comparison of the sensitivity of Shikonin.
Techniques Used:
Figure Legend Snippet: The differential expression of CADM1-CADM1 between tumor tissues and normal tissues in pan-cancer (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05).
Techniques Used: Expressing
Figure Legend Snippet: The expression of CADM1-CADM1 in PTC cell lines. (A) The different expression of CADM1 in N3, K1, BAPAP, TPC1 and IHH4 cell lines. (B) Results of immunofluorescence staining of IHH4 cells, which were mainly located in cytoplasm and a little in nucleus. (C) Results of immunofluorescence staining of TPC1 cells, which were also mainly located in cytoplasm and a little in nucleus. (D–I) Overexpression of CADM1 in IHH4 cell lines by pEGFP-C1-CADM1 transfection inhibits cell migration. D, Blank control (IHH4) (×200). E, pEGFP-C1 (NC) (×200). F, pEGFP-C1-CADM1 (CADM1) (×200). (G–I) Overexpression of CADM1 in TPC1 cell lines by pEGFP-C1-CADM1 transfection inhibits cell migration. G, Blank control (TPC1) (×200).H, pEGFP-C1 (NC) (×200). I, pEGFP-C1-CADM1 (CADM1) (×200).
Techniques Used: Expressing, Immunofluorescence, Staining, Over Expression, Transfection, Migration
